Cinaciguat is the first of a class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.
规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Cinaciguat at 10 μM substantially boosts the production of intracellular cGMP, yet shows no dose-dependent impacts on cell contraction or calcium transient changes[2]. |
Animal study | Administering Cinaciguat at a dose of 10 mg/kg/day orally to diabetic rats does not alter blood glucose levels, however, it reduces water consumption. Cinaciguat treatment also mitigates oxidative stress related to diabetes mellitus, protects against alterations in the NO-sGC-cGMP-PKG pathway, and reduces myocardial hypertrophy and apoptosis associated with diabetes mellitus[1].Cinaciguat at concentrations of 1, 10, and 100 nM elicits concentration-dependent relaxations in gastrointestinal smooth muscle strips from both WT and apo-sGC mice, although it does not affect phasic activity caused by PGF2α in these muscle strips[3]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.77mL 0.35mL 0.18mL |
8.84mL 1.77mL 0.88mL |
17.68mL 3.54mL 1.77mL |
CAS号 | 329773-35-5 |
分子式 | C36H39NO5 |
分子量 | 565.7 |
SMILES Code | OC(C(C=C1)=CC=C1CN(CCCCC(O)=O)CCC(C=CC=C2)=C2OCC(C=C3)=CC=C3CCC4=CC=CC=C4)=O |
MDL No. | MFCD18782678 |
别名 | BAY 58-2667 |
运输 | 蓝冰 |
InChI Key | WPYWMXNXEZFMAK-UHFFFAOYSA-N |
Pubchem ID | 9808022 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Inert atmosphere, store in freezer, under -20°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|